Ming Shi

发表

CRISPR screen in mechanism and target discovery for cancer immunotherapy

Xuan Zhao, Junnian Zheng, Shuci Liu, 2020 .

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Hong Liu, Junnian Zheng, J. Qiao, 2021, Frontiers in Immunology.

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

Kailin Xu, L. Zeng, Jiang Cao, 2022, Frontiers in Immunology.

Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia

Hui Gao, Junnian Zheng, Kailin Xu, 2021, Journal of cellular and molecular medicine.

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

Bing Zhang, Junnian Zheng, Kailin Xu, 2020, Cancer medicine.

Coagulation Disorders after CAR T Cell Therapy: Analysis of 100 Patients with R/R Hematologic Malignancies.

Junnian Zheng, K. Qi, J. Qiao, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.

Junnian Zheng, Gang Wang, J. Zhao, 2019, The Lancet. Haematology.

Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia

R. Gale, Junnian Zheng, Huizhong Li, 2022, American journal of hematology.

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy

Junnian Zheng, Kailin Xu, Jiang Cao, 2021, Frontiers in Immunology.

Potent anti‐leukemia activities of humanized CD19‐targeted Chimeric antigen receptor T (CAR‐T) cells in patients with relapsed/refractory acute lymphoblastic leukemia

J. Zhao, Junnian Zheng, Huizhong Li, 2018, American journal of hematology.

Neural regulation of drug resistance in cancer treatment.

Junnian Zheng, Zhongwei Li, Dan Liu, 2019, Biochimica et biophysica acta. Reviews on cancer.

Kinetics of immune reconstitution after anti‐CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients

Junnian Zheng, K. Zhao, K. Qi, 2020, International journal of laboratory hematology.

Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment

Junnian Zheng, Kailin Xu, Jiang Cao, 2020, Bone Marrow Transplantation.

Rui Hou, Dan Liu, Wen Ma, 2022, Frontiers in Immunology.

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

Xuan Zhao, Rui Hou, Dan Liu, 2022, Frontiers in Immunology.

Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection

R. Gale, Junnian Zheng, Xi Zhang, 2020, Leukemia.

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma

Yuekun Qi, A. Liang, K. Qi, 2022, Frontiers in Immunology.

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.

Junnian Zheng, K. Qi, Kailin Xu, 2021, Transplantation and cellular therapy.

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma

Huizhong Li, Gang Wang, Kailin Xu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour-associated macrophages enhance breast cancer malignancy via inducing ZEB1-mediated DNMT1 transcriptional activation

Zhongwei Li, Ming Shi, H. Yong, 2022, Cell & Bioscience.

Humanized CD19‐targeted chimeric antigen receptor T (CAR‐T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia

Junnian Zheng, Gang Wang, K. Qi, 2021, American journal of hematology.

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma

J. Qiao, Kailin Xu, L. Zeng, 2022, Frontiers in Immunology.

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Junnian Zheng, Jianfeng Zhou, A. Liang, 2021, Blood advances.

ATPIF1 inactivation promotes antitumor immunity through metabolic reprogramming of CD8+ T cells

Jianping Ye, Xiaoying Zhang, Yinming Liang, 2020, bioRxiv.

Expression of CHPF modulates cell proliferation and invasion in lung cancer

Junnian Zheng, Chengsong Cao, Jing Zhao, 2020, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Potential of CRISPR screen in target discovery for cancer immunotherapy.

Xuan Zhao, Junnian Zheng, Shuci Liu, 2020, Biochimica et biophysica acta. Reviews on cancer.

Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.

K. Qi, J. Qiao, Hai Cheng, 2024, Cytotherapy.

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

He Huang, Yuekun Qi, Jianfeng Zhou, 2022, Blood.

Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia

Junnian Zheng, Huizhong Li, Gang Wang, 2019, Leukemia.